Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in India
Introduction: Hyperleukocytosis (HL) and leukostasis seen in myeloid leukemias are a medical emergency. We present a case series of ten such patients in a 4-year period. Sixteen therapeutic leukocyte reduction (TLR) were done in ten cases along with other supportive measures. The American Society fo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Asian Journal of Transfusion Science |
| Subjects: | |
| Online Access: | http://www.ajts.org/article.asp?issn=0973-6247;year=2017;volume=11;issue=2;spage=156;epage=161;aulast=Tendulkar |
| _version_ | 1818560734821351424 |
|---|---|
| author | Anita A Tendulkar Puneet A Jain Abhaykumar Gupta Nidhi Sharma Anisha Navkudkar Vijaya Patle |
| author_facet | Anita A Tendulkar Puneet A Jain Abhaykumar Gupta Nidhi Sharma Anisha Navkudkar Vijaya Patle |
| author_sort | Anita A Tendulkar |
| collection | DOAJ |
| description | Introduction: Hyperleukocytosis (HL) and leukostasis seen in myeloid leukemias are a medical emergency. We present a case series of ten such patients in a 4-year period. Sixteen therapeutic leukocyte reduction (TLR) were done in ten cases along with other supportive measures. The American Society for Apheresis supports the routine implementation of TLR in cases of HL secondary to myeloid leukemias with signs of leukostasis.
Materials and Methods: The procedures were performed on the intermittent flow cell separator after discussion with the treating physician about patient's condition. Clinical, demographic, analytical, and technical variables were reviewed retrospectively and the patients were followed up at the end of 4 years. Descriptive analysis was performed for all variables, and relationships between quantitative variables and categorical variables were determined by applying the Student's t-test.
Results: The mean age of presentation was 34 years. Priapism was the most common symptom followed by respiratory distress and neurological disturbances. After an average of 1.6 TLR procedures, the mean leukocyte count reduction achieved was 39.9% along with symptomatic relief. The mean survival at 4-year follow-up was 12.8 months and the overall mortality was 20%. Acute myeloid leukemia patients presented with lower mean platelet counts compared to chronic myeloid leukemia patients; however, the platelet loss in the final product was minimized.
Conclusion: TLR is a safe and effective therapy for leukoreduction in hematological malignancies in our experience. |
| first_indexed | 2024-12-14T00:42:04Z |
| format | Article |
| id | doaj.art-aee4118ef3c5445ea8d443f73c8e96af |
| institution | Directory Open Access Journal |
| issn | 0973-6247 1998-3565 |
| language | English |
| last_indexed | 2024-12-14T00:42:04Z |
| publishDate | 2017-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Asian Journal of Transfusion Science |
| spelling | doaj.art-aee4118ef3c5445ea8d443f73c8e96af2022-12-21T23:24:20ZengWolters Kluwer Medknow PublicationsAsian Journal of Transfusion Science0973-62471998-35652017-01-0111215616110.4103/ajts.AJTS_103_16Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in IndiaAnita A TendulkarPuneet A JainAbhaykumar GuptaNidhi SharmaAnisha NavkudkarVijaya PatleIntroduction: Hyperleukocytosis (HL) and leukostasis seen in myeloid leukemias are a medical emergency. We present a case series of ten such patients in a 4-year period. Sixteen therapeutic leukocyte reduction (TLR) were done in ten cases along with other supportive measures. The American Society for Apheresis supports the routine implementation of TLR in cases of HL secondary to myeloid leukemias with signs of leukostasis. Materials and Methods: The procedures were performed on the intermittent flow cell separator after discussion with the treating physician about patient's condition. Clinical, demographic, analytical, and technical variables were reviewed retrospectively and the patients were followed up at the end of 4 years. Descriptive analysis was performed for all variables, and relationships between quantitative variables and categorical variables were determined by applying the Student's t-test. Results: The mean age of presentation was 34 years. Priapism was the most common symptom followed by respiratory distress and neurological disturbances. After an average of 1.6 TLR procedures, the mean leukocyte count reduction achieved was 39.9% along with symptomatic relief. The mean survival at 4-year follow-up was 12.8 months and the overall mortality was 20%. Acute myeloid leukemia patients presented with lower mean platelet counts compared to chronic myeloid leukemia patients; however, the platelet loss in the final product was minimized. Conclusion: TLR is a safe and effective therapy for leukoreduction in hematological malignancies in our experience.http://www.ajts.org/article.asp?issn=0973-6247;year=2017;volume=11;issue=2;spage=156;epage=161;aulast=TendulkarHyperleukocytosisleukemialeukocytapheresistherapeutic leukocyte reductiontumor lysis syndrome |
| spellingShingle | Anita A Tendulkar Puneet A Jain Abhaykumar Gupta Nidhi Sharma Anisha Navkudkar Vijaya Patle Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in India Asian Journal of Transfusion Science Hyperleukocytosis leukemia leukocytapheresis therapeutic leukocyte reduction tumor lysis syndrome |
| title | Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in India |
| title_full | Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in India |
| title_fullStr | Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in India |
| title_full_unstemmed | Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in India |
| title_short | Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in India |
| title_sort | therapeutic leukocyte reduction for acute and chronic myeloid leukemias a 4 year experience from an oncology center in india |
| topic | Hyperleukocytosis leukemia leukocytapheresis therapeutic leukocyte reduction tumor lysis syndrome |
| url | http://www.ajts.org/article.asp?issn=0973-6247;year=2017;volume=11;issue=2;spage=156;epage=161;aulast=Tendulkar |
| work_keys_str_mv | AT anitaatendulkar therapeuticleukocytereductionforacuteandchronicmyeloidleukemiasa4yearexperiencefromanoncologycenterinindia AT puneetajain therapeuticleukocytereductionforacuteandchronicmyeloidleukemiasa4yearexperiencefromanoncologycenterinindia AT abhaykumargupta therapeuticleukocytereductionforacuteandchronicmyeloidleukemiasa4yearexperiencefromanoncologycenterinindia AT nidhisharma therapeuticleukocytereductionforacuteandchronicmyeloidleukemiasa4yearexperiencefromanoncologycenterinindia AT anishanavkudkar therapeuticleukocytereductionforacuteandchronicmyeloidleukemiasa4yearexperiencefromanoncologycenterinindia AT vijayapatle therapeuticleukocytereductionforacuteandchronicmyeloidleukemiasa4yearexperiencefromanoncologycenterinindia |